The Innovative Health Initiative (IHI)
Presentation of industry Founding Members

Joanna Wills
Research Manager Northern Europe, GE Healthcare; Co-chair, COCIR Research & Innovation Panel

Bernd Stowasser
Head of Sanofi Partnering Germany; Global Head of Sanofi Public Private Partnerships; Alliance Management - Member of the EFPIA Research & Innovation Strategy (RIS) Group and Chair of the RIS Core Group

IHI Infoday Italy – 21 July 2022
WHAT IS IHI?

IHI is a collaboration between the EU and the biopharmaceutical, biotechnology, digital health and medical technology sectors, as well as academics, patients, regulators and other healthcare professionals.

FROM IMI TO IHI

IHI will build on the extensive experience of IMI’s 14 years and almost 200 projects to build an interdisciplinary, sustainable, patient-centric health research partnership to help transform patients’ lives.

IHI PARTNERS

The industry members that make up the new partnership are:

- COCIR
- EFPIA
- EuropaBio
- MedTech Europe
- Vaccines Europe

The public member in the partnership is the European Union, represented by the European Commission.

COCIR
EFPIA
MedTech Europe
EuropaBio
Vaccines Europe
IHI industry Founding Members


www.cocir.org  www.medtecheurope.org
IHI JU Budget

IHI will work to reach its objectives with the following resources:

- up to EUR **1.2 billion** provided by the European Union (Horizon Europe Health Cluster),
- at least EUR **1.0 billion** provided by the member industry associations
- up to EUR **200 million** from Contributing Partners.

→ Commitment to at least **match at programme level** the EU funding with industry and CP contributions
→ Industry participants encouraged to submit proposals with budget including **at least 50% in-kind contributions** (i.e. above the 45% minimal eligibility requirement)
IHI JU Budget (€ million)
Contributions by founding members

- EC, 1200
- Contributing partners, 200
- EFPIA-VE-EuropaBio, 500
- COCIR, 250
- MTE, 250
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe.

**Our vision**
EFPIA’s vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients.

**Our mission**
EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
About EFPIA

- 56 staff members
- 38 member companies
- 37 member associations
- 17 SMEs
- 36 partners in research
- 15 Members
EFPIA MEMBER COMPANIES

Full members

AbbVie  Almirall  AMGEN  Astellas  AstraZeneca  Bayer  Biogen  Boehringer Ingelheim  Bristol-Myers Squibb  Chiesi  Daiichi-Sankyo  Gilead  GlaxoSmithKline  Ipsen  Johnson & Johnson  Leo  Lilly  Merck  MSD  Novartis  Novo Nordisk  Pfizer  Pierre Fabre  Roche  Sanofi  Servier  Takeda  Teva  UCB

Affiliate members

Bial  Eisai  Esteve  Lundbeck  Otsuka  Rovi  Stallergenes  Vifor Pharma
SME members

EFPIA MEMBER COMPANIES
Partners in Research

EFPIA MEMBER COMPANIES
Vaccines Europe (VE) is the specialised vaccine industry group within EFPIA. It represents major innovative research-based global vaccine companies as well as small and medium sized enterprises operating in Europe.

Vaccines Europe Members
Members of FarmIndustria:
- are considered as EFPIA for the purpose of IHI
- can contribute eligible in-kind contributions
A decade of successes

Examples:

• Ebola vaccines and diagnostics,
• New candidate antibiotics,
• Tools to predict toxicity approved by regulators,
• Standards that opened the path to autism medicines research,
• 70 novel drug targets, 35 validated drug targets,
• Several clinical trials networks (1800 sites across Europe) and 39 cohorts and registries to optimise clinical trials,
• Developed manufacturing method of flucytosine that dramatically cuts production cost,
• Outcomes (real world data) data infrastructure and governance established,
• First ever human beta cell line culture which changed the way diabetes research is done
From IMI to IHI
The value of Public Private Partnerships Europe’s Partnership for Health

The Innovative Medicines Initiative: the largest public-private partnership for health research worldwide
€5,276 billion
IMI1 €2 billion from 2008 – 2014
IMI2 €3,276 billion from 2014 - 2024
Part of the EU FP7 and Horizon 2020 R&D funding

The Innovative Health Initiative
- Budget over 7 years
  - €1.2 billion EU funding from EC
  - €1.2 billion contribution from industry and contributing partners
- Institutional partnership with the EU (Joint Undertaking)
- Cross sectoral between
  - Pharmaceutical and biotech sector (EFPIA, Vaccines Europe, EuropaBio)
  - medical technologies sector (MedTech Europe, COCIR)
EuropaBio Mission

EuropaBio is the voice of biotechnology in Europe

delivering an innovation pipeline for a competitive industry

EuropaBio works with company members and national associations across sectors:

• Bringing **Innovation** to all citizens

• Enabling **Investment** to deliver next generation technologies to market

• Delivering **Excellence** across science and society

**Healthy people and planet**
A snapshot of members
The medtech industry associations

- Medical device
- Medical devices
- In vitro diagnostic
- Digital health

- Radiotherapy
- Medical imaging
- Health ICT
- Electromedical
Introduction to COCIR

- COCIR is a non-profit trade association, founded in 1959 and having offices in Brussels and China, representing the medical technology industry in Europe.
- COCIR covers 4 key industry sectors:
  - Medical Imaging
  - Radiotherapy
  - Health ICT
  - Electromedical
- Our Industry leads in state-of-art advanced technology and provides integrated solutions covering the complete care cycle.
MedTech Europe’s purpose is to make innovative medical technologies available to more people, while helping healthcare systems move towards a more sustainable path.

**MISSION**

- Be the European voice of the medical technology industries – in Europe and beyond.
- Facilitate access to needed medical technologies.
- Contribute actively to EU health-related policies and legislations.
- Highlight the value and contribution of medical technologies, services and solutions for patients, healthcare systems and society.
- Be a trusted partner to EU policymakers and key stakeholders.
- Foster the highest ethical standards in all interactions between the industry and HCPs and HCOs.
MedTech Europe organisation

Based in Brussels, Belgium with 50 staff

• Digital Health
• Environmental Policy
• External Affairs
• International Affairs
• Legal and Compliance
• Market Access and Economic Policy
• Market Data
• Regulatory and Industrial Policy
• Research and Innovation
Healthcare stakeholders
Potential participants to projects

- Citizens
- Patients
- Carers

- Academia
- RTOs
- Learned societies

- Research
- Infrastruct.

- EU and
- National
- Regulators

- Industries
- all sectors
- & sizes

- Healthcare
- Systems

- Healthcare
- Professionals

- Member
- States
Shape IHI’s future research and get involved

• **Become an evaluator / independent observer**

• **Join the Patient Pool** (to be re-opened later this year)
  [ihi.europa.eu/projects-results/health-spotlights/impact-patients-research](ihi.europa.eu/projects-results/health-spotlights/impact-patients-research)

• **Propose new ideas**
  [ihi.europa.eu/shape-our-future-research/propose-ideas](ihi.europa.eu/shape-our-future-research/propose-ideas)

• **Contribute at programme level:**
  - join an industry association (European or national member associations)
  - become a Contributing Partner
    [ihi.europa.eu/shape-our-future-research/become-contributing-partner](ihi.europa.eu/shape-our-future-research/become-contributing-partner)

• **Apply to IHI Calls**
IHI Calls 2022

• **Calls 1 and 2**
  - Launched on 28 June
  - Proposal submission deadline: 20 September
    → [https://www.ihi.europa.eu/apply-funding/open-calls](https://www.ihi.europa.eu/apply-funding/open-calls)

• **Calls 3 and 4** – launch expected by end 2022 (indicative):
  - October – November: release of draft versions (indicative)
  - **Call 3 - Single stage:**
    - Mid-December 2022: call launch
    - Mid-March 2023: full proposal submission deadline
  - **Call 4 – Two-stage:**
    - Mid-January 2023: call launch
    - Mid-April 2023: short proposal submission deadline
IHI Calls 1 & 2: Recorded webinars


- **IHI rules and procedures**: 10 June (10:30-12:00)
- **Preparing the financial part of the proposal**: 27 June (14:30-16:00)
- **Call 1**:
  - Next generation imaging and image-guided diagnosis and therapy for cancer: 15 June (14:30-16:00)
  - Access and integration of heterogeneous health data for improved health care in diseases areas of high unmet public health need: 22 June (10:30-12:00)
  - Personalised oncology: Innovative people-centred, multi-modal therapies against cancer: 23 June (10:30-12:00)
  - An innovative decision-support system for improved care pathways for patients with neurodegenerative diseases and comorbidities: 23 June (14:30-16:00)
- **Call 2**:
  - Cardiovascular diseases – improved prediction, prevention, diagnosis and monitoring: 22 June (14:30-16:00)
  - Setting a harmonised methodology to promote uptake of early feasibility studies for clinical and innovation excellence in the EU: 16 June (14:00-16:00)
IHI Calls 1 & 2: Brokerage event platform

Platform still online until proposal submission: new participants can still register to network with potential applicants / coordinators → https://ihi-calls-2022.b2match.io/

Welcome to
IHI Kick-off and brokerage event

Learn how to be part of IHI's first projects, and find the best partners for your consortium.

The Innovative Health Initiative (IHI) will launch its first calls for proposals in June 2022. The aim of this event is to provide potential applicants with the information they need to put together a strong proposal, and give them the opportunity to identify and meet partners for their consortia.
Thank you for your attention